Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency
Authors:
Top Cited Papers
- 10 June 2025
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (22) , 1965
Abstract
Importance: Uncertainty remains about the efficacy of intravenous iron in patients with heart failure and iron deficiency.Objective: To assess the efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency.Design, Setting, and Participants: This multicenter, randomized clinical trial enrolled 1105 patients with heart failure (defined as having a left ventricular ejection fraction of ≤45%) and iron deficiency (serum ferritin level P ≤ .05 for all 3 of the end point comparisons, (2) P ≤ .025 for 2 of the end point comparisons, or (3) P ≤ .0167 for any of the 3 end point comparisons (Hochberg procedure).Results: Of the 1105 participants (mean age, 70 years [SD, 12 years]; 33% were women), cardiovascular death or first heart failure hospitalization (first primary outcome) occurred in 141 in the ferric carboxymaltose group vs 166 in the placebo group (hazard ratio, 0.79 [95% CI, 0.63-0.99]; P = .04). The second primary outcome (total heart failure hospitalizations) occurred 264 times in the ferric carboxymaltose group vs 320 times in the placebo group (rate ratio, 0.80 [95% CI, 0.60-1.06]; P = .12). The third primary outcome (cardiovascular death or first heart failure hospitalization in patients with a transferrin saturation P = .07). A similar amount of patients had at least 1 serious adverse event in the ferric carboxymaltose group (269; 48.2%) vs in the placebo group (273; 49.9%) (P = .61).Conclusions and Relevance: In patients with heart failure and iron deficiency, ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death in the overall cohort or in patients with a transferrin saturation less than 20%, or reduce the total number of heart failure hospitalizations vs placebo.Trial Registration: ClinicalTrials.gov Identifier: NCT03036462Keywords
This publication has 23 references indexed in Scilit:
- Rationale and Design of the FAIR-HF2-DZHK05 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart FailureEuropean Journal of Heart Failure, 2025
- Critical Re-Evaluation of the Identification of Iron Deficiency States and Effective Iron Repletion Strategies in Patients with Chronic Heart FailureEuropean Journal of Heart Failure, 2024
- Ferric Carboxymaltose in Heart Failure with Iron DeficiencyNew England Journal of Medicine, 2023
- Effect of Intravenous Iron Replacement on Recurrent Heart Failure Hospitalizations and Cardiovascular Mortality in Patients with Heart Failure and Iron Deficiency: A Bayesian Meta-AnalysisEuropean Journal of Heart Failure, 2023
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialThe Lancet, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialThe Lancet, 2020
- Iron Deficiency in Heart FailureJACC: Heart Failure, 2019
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron DeficiencyJACC, 2008